Document is current
Any future updates will be listed below
-
Authors
Stover, Angela M. https://orcid.org/0000-0003-0983-686X
Liang, Debbie
Mueller, Dana
Kurtzman, Rachel
Ikemeh, Christiana
Canter, Courtney
Acharya, Sonali
Brese, Jill
Buhlinger, Kaitlyn
Chen, Kevin
Colmenares, Evan W.
Faso, Aimee
Muluneh, Benyam
Patel, Bianka
Reichard, Jeffrey S.
Shah, Rushabh M.
Tilkens, Michael
Valgus, John
Coombs, Lorinda A.
Lafata, Jennifer Elston
Lund, Jennifer L.
Ray, Emily M.
Mody, Gita
Vest, Mary-Haston
-
Funding
Funding for this research was provided by:
National Institute on Aging (R21AG059206/R33AG059206)
Pfizer
Hematology/Oncology Pharmacy Association
NCATS/NIH (UL1TR002489)
- License Information
-
More Information
Article History
Accepted: 8 September 2024
First Online: 15 October 2024
Declarations
:
: AMS: unrelated funding in the past two years from Sivan Innovation, UroGen Pharma Ltd., and the American Society of Clinical Oncology (all awarded to institution). Dr. Stover received a honorarium for serving on the steering committee for PROTEUS. LAC: serves on the Board of Directors for APSHO. GM: Unrelated research funding from Sivan Innovation. KC: Unrelated consulting fees or speaking honoraria in the last 24 months from: Pfizer, Blueprint Medicines, G1 Therapeutics. JLL: In the last 24 months, Dr. Lund’s spouse was employed by GSK and owned stock in the company. Dr. Lund is also a member of one of the sponsors funding this work, the Cancer and Aging Research Group (CARG). MHV and DL: unrelated Pfizer funding. EMR: unrelated research funding from Pfizer, OptumHealth, and the American Society of Clinical Oncology (awarded to institution). RS: consultant for the American Society of Health-System Pharmacists on an unrelated project. JEL: unrelated funding from Genentech (awarded to institution). DM, RK, CI, CC, SA, JB, KB, EWC, AF, BM, BP, JSR: none.ma Ltd., and the American Society of Clinical Oncology (all awarded to institution). Dr. Stover received a honorarium for serving on the steering committee for PROTEUS. LAC: serves on the Board of Directors for APSHO. GM: Unrelated research funding from Sivan Innovation. KC: Unrelated consulting fees or speaking honoraria in the last 24 months from: Pfizer, Blueprint Medicines, G1 Therapeutics. JLL: In the last 24 months, Dr. Lund’s spouse was employed by GSK and owned stock in the company. Dr. Lund is also a member of one of the sponsors funding this work, the Cancer and Aging Research Group (CARG). MHV and DL: unrelated Pfizer funding. EMR: unrelated research funding from Pfizer, OptumHealth, and the American Society of Clinical Oncology (awarded to institution). RS: consultant for the American Society of Health-System Pharmacists on an unrelated project. JEL: unrelated funding from Genentech (awarded to institution). DM, RK, CI, CC, SA, JB, KB, EWC, AF, BM, BP, JSR: none.
: Patients gave verbal informed consent for telephone interviews (IRB# 22-0745) and the remainder of activities were exempt from oversight (IRB# 22-1466).
